Medical cannabis-related stigma: cancer survivors' perspectives.

Autor: Nayak MM; Department of Psychosocial Oncology and Palliative Care, Dana-Farber Cancer Institute, Boston, MA, USA. manan_nayak@dfci.harvard.edu.; Phyllis F. Cantor Center for Research in Nursing and Patient Care Services, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA, LW-51902215, USA. manan_nayak@dfci.harvard.edu.; Harvard Medical School, Boston, MA, USA. manan_nayak@dfci.harvard.edu., Revette A; Survey and Qualitative Methods Core, Department of Population Sciences, Dana-Farber Cancer Institute, Boston, MA, USA., Chai PR; Department of Emergency Medicine, Brigham and Women's Hospital, Boston, MA, USA.; The Koch Institute for Integrated Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.; The Fenway Institute, Boston, MA, USA., Lansang K; School of Nursing, University of California Los Angeles, Los Angeles, CA, USA., Sannes T; Department of Psychosocial Oncology and Palliative Care, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA., Tung S; Department of Psychosocial Oncology and Palliative Care, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA., Braun IM; Department of Psychosocial Oncology and Palliative Care, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.
Jazyk: angličtina
Zdroj: Journal of cancer survivorship : research and practice [J Cancer Surviv] 2023 Aug; Vol. 17 (4), pp. 951-956. Date of Electronic Publication: 2022 Nov 26.
DOI: 10.1007/s11764-022-01297-7
Abstrakt: Background: Although the vast majority of medical cannabis laws in the USA includes cancer as a qualifying condition and medical cannabis-related stigma influences decision-making regarding the botanical, few studies have explored the phenomenon in oncology. Early findings indicated oncologic cannabis-related stigma to be quite widespread.
Methods: Semi-structured interviews with 24 adults with cancer histories using medical cannabis were analyzed using the Health Stigma and Discrimination Framework.
Results: Sixteen out of 24 participants discussed medical cannabis-related stigma in some depth. The phenomena emerged as more pervasive in medical than personal/professional domains and was internalized as well as experienced directly. It led some participants, but not others, to practice partial or complete secrecy.
Discussion: Taken together, our findings suggest that, while medical cannabis-related stigma remains widespread and led some study participants to alter behavior, an early shift in ethos towards greater medical cannabis acceptance could be underway. If so, this transition may be occurring more rapidly in non-medical than in clinical settings.
Conclusion: Cancer survivors may experience heightened medical cannabis-related stigma in the clinic as compared to their personal/professional lives. Healthcare providers who depend on patient transparency when gathering medical histories and devising care plans may wish to neutralize perceptions of medical cannabis-related stigma.
(© 2022. The Author(s).)
Databáze: MEDLINE
Externí odkaz: